Author of

• 13707

  +

  P1.06 - Poster Session/ Screening and Early Detection (ID 218)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Screening and Early Detection
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13715

    +

    P1.06-008 - Functional Polymorphisms in PD-L1 Gene Are Associated with the Prognosis of Patients with Early Stage Non-Small Cell Lung Cancer (ID 1124)

    09:30 - 09:30  |  Author(s): C.C. Jin
    • Abstract
    • Slides

    Background:
    This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the prognosis of patients with early stage non-small cell lung cancer (NSCLC) after surgical resection.
    
    Methods:
    Twelve single nucleotide polymorphisms (SNPs) of PD-1, PD-L1, and CTLA-4 genes were selected and genotyped. A total of 354 patients with early stage NSCLC who underwent curative surgical resection were enrolled. The association of the SNPs with overall survival (OS) was analyzed.Twelve single nucleotide polymorphisms (SNPs) of PD-1, PD-L1, and CTLA-4 genes were selected and genotyped. A total of 354 patients with early stage NSCLC who underwent curative surgical resection were enrolled. The association of the SNPs with overall survival (OS) was analyzed.
    
    Results:
    Among the 12 SNPs investigated, PD-L1 SNP1C>G, SNP2G>C, and SNP3T>A were significantly associated with worse survival outcomes in multivariate analyses. When the three SNPs were combined, OS decreased in a dose-dependent manner as the number of bad genotypes increased (Ptrend = 0.0003). A higher expression of the reporter gene for the SNP2G- SNP3T haplotype was observed compared with the SNP2C- SNP3A haplotype by luciferase assay (P = 0.004). Patients with higher expression of PD-L1 mRNA had a better survival compared with lower expression (P = 0.03).
    
    Conclusion:
    PD-L1 SNP1C>G, SNP2G>C, and SNP3T>A polymorphisms may be useful for the prediction of prognosis in patients with surgically resected NSCLC. Further studies are needed to confirm our findings and to understand the role of PD-L1 in the antitumor immunity.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.